Mindset

Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Mindset Pharma (MSET.C) announced that they have filed an international patent for their novel psilocybin synthesis method. The application covers Mindset’s Synthesis Process, a process they call “ground-breaking” and…
Mindset Pharma (MSET.C) announced their lead clinical candidate, MSP-1014. MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSET plans on moving forward…
Mindset Pharma (MSET.C) announced that their in vivo (in an animal) testing carried out by InterVivo Solutions confirmed that the majority of their patent-pending compounds created effects that correlate…
Mindset Pharma (MSET.C) announced they have completed their $7.5 million “bought deal” public offering. The offering issued 10,000,000 units sold at $0.75 each. Each unit granted the buyer one…